Glaukos

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Glaukos and other ETFs, options, and stocks.

About GKOS

Glaukos Corp. is an ophthalmic medical technology and pharmaceutical company, which focuses on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It engages in development and commercialization of therapies across several end markets within ophthalmology.

CEO

Thomas William Burns

CEOThomas William Burns

Employees

907

Employees907

Headquarters

Aliso Viejo, California

HeadquartersAliso Viejo, California

Founded

1998

Founded1998

Employees

907

Employees907

GKOS Key Statistics

Market cap

5.28B

Market cap5.28B

Price-Earnings ratio

-35.57

Price-Earnings ratio-35.57

Dividend yield

—

Dividend yield—

Average volume

464.49K

Average volume464.49K

High today

$108.22

High today$108.22

Low today

$97.00

Low today$97.00

Open price

$97.00

Open price$97.00

Volume

845.41K

Volume845.41K

52 Week high

$108.22

52 Week high$108.22

52 Week low

$45.38

52 Week low$45.38

GKOS News

Benzinga 5h

Eye Disease-Focused Glaukos' 'Investor Interest Should Continue To Gain Momentum:' Analyst

Loading... Loading... Thursday, Glaukos Corporation GKOS reported a first-quarter adjusted EPS loss of $(0.70), up from $(0.59) a year ago, missing the consens...

TipRanks 1d

Glaukos First-Quarter 2024 Financial Performance Overview - TipRanks.com - TipRanks

Glaukos (GKOS) has shared an update. Glaukos Corporation has released its first-quarter financial summary for 2024, offering investors a glimpse into the compa...

TipRanks 1d

Glaukos reports Q1 EPS (70c), consensus (57c)

Reports Q1 revenue $85.6M, consensus $79.6M. “Our record first quarter results reflect successful global execution of our key strategic plans,” said Thomas Burn...

Analyst ratings

67%

of 15 ratings

Buy

66.7%

Hold

33.3%

Sell